Ventria Bioscience partners with BMGF to address pediatric diarrhea in the developing world

In our last post, we discussed results from a re-analysis of theGlobal Enteric Multicenter Study(GEMS), which found that the key pathogens responsible for nearly 80% of worldwide cases of pediatric diarrhea areShigella spp, rotavirus, adenovirus 40/41,heat-stable enterotoxigenicE. coli (ETEC), Cryptosporidium spp,andCampylobacter spp.Previously, we also discussed a study, sponsored by Ventria Bioscience, into how recombinant human breastmilk properties with antimicrobial and anti-inflammatory properties could have potential therapeutic benefit for children suffering from diarrhea.

How do these items relate to each other, specifically? In 2017, Ventria Bioscience announced it had received a $4.2 million grant from the Bill & Melinda Gates Foundation to help develop ExpressTec manufacturing methods to produce its therapeutic candidate,1mantbex . The purpose of VEN BETA will be to reduce the morbidity and mortality associated with ETEC, which accounts for an estimated 280 million to 400 million cases of diarrhea a year in children under five and an estimated 157,000 deaths per year.

Read more about the grant from the Bill and Melinda Gates Foundation.